Squarepoint Ops LLC Trims Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Squarepoint Ops LLC trimmed its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 58.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 42,490 shares of the company's stock after selling 60,696 shares during the quarter. Squarepoint Ops LLC owned 0.07% of Ginkgo Bioworks worth $417,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Forbes J M & Co. LLP lifted its stake in Ginkgo Bioworks by 461.4% in the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after purchasing an additional 576,732 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Ginkgo Bioworks in the fourth quarter worth about $29,000. Barclays PLC lifted its stake in shares of Ginkgo Bioworks by 353.6% in the 4th quarter. Barclays PLC now owns 54,166 shares of the company's stock valued at $531,000 after acquiring an additional 42,224 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Ginkgo Bioworks by 65.1% in the 4th quarter. Renaissance Technologies LLC now owns 114,654 shares of the company's stock valued at $1,126,000 after acquiring an additional 45,200 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Ginkgo Bioworks during the 4th quarter valued at about $199,000. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Stock Performance

DNA traded up $0.25 on Monday, hitting $7.84. 904,376 shares of the company were exchanged, compared to its average volume of 1,450,707. The firm has a fifty day simple moving average of $7.31 and a two-hundred day simple moving average of $9.05. The stock has a market capitalization of $458.89 million, a PE ratio of -0.60 and a beta of 1.25. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $22.60.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). The firm had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. On average, equities analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.